Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[211At]APA (also known as TLX102 or [211At]4-astato-L-phenylalanine) is an investigational targeted alpha-therapy (TAT) radiopharmaceutical being developed by Telix Pharmaceuticals. It is a small-molecule L-phenylalanine analogue radiolabeled with the alpha-emitting radionuclide astatine-211 (211At). The drug selectively targets and accumulates in tumor cells via the L-type amino acid transporter 1 (LAT1, also known as SLC7A5), which is highly overexpressed in various cancers, including glioblastoma and multiple myeloma. By delivering high-energy, short-range alpha radiation directly to cancer cells, [211At]APA aims to induce lethal DNA double-strand breaks while minimizing damage to surrounding healthy tissues. It is being developed for the treatment of glioblastoma, leptomeningeal disease, and multiple myeloma, and has received Orphan Drug Designation from the U.S. FDA for multiple myeloma and glioma.
| Indication | Highest phase | Status |
|---|---|---|
| glioblastoma, IDH-wildtype | Preclinical | Active |
| multiple myeloma (MM) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: glioblastoma, IDH-wildtype
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [211At]APA.
Work on [211At]APA? Claim this page to correct or add information. Claim this page